Abbott Laboratories

Abbott Laboratories was ordered to pay $53 million in compensatory damages by a Cook County jury for failing to warn that its formula for premature infants can cause necrotizing enterocolitis (NEC). This verdict is part of ongoing litigation, with hundreds of lawsuits filed against the company, and could lead to further financial penalties, including punitive damages. The CEO has suggested the company might pull its preterm products due to litigation.

Abbott Laboratories is using a phased retirement approach with reverse mentoring to transfer critical knowledge from experienced employees like Robert Poole to younger engineers like Shahad Almahania, ensuring continuity in specialized operations.

Abbott Laboratories is recognized as a significant company in the peripheral vascular devices market, contributing to and benefiting from the market's projected growth.

Abbott Laboratories slumped 6% and hit its lowest level since November 2023 after cutting its full-year profit forecast, negatively impacting its stock performance.

Abbott Laboratories fell despite slightly better-than-expected results, due to a cut in its full-year profit forecast primarily because of its acquisition of Exact sciences.